References from Real-world Outcomes of First-line Enfortumab Vedotin Plus Pembrolizumab in Elderly Patients With Advanced Urothelial Carcinoma. Local targets link to admitted publications; unresolved targets remain external evidence.
No reference evidence is available for this admitted work.
References for Real-world Outcomes of First-line Enfortumab Vedotin Plus Pembrolizumab in Elderly Patients With Advanced Urothelial Carcinoma | ResearchHub - ResearchHub
